检索结果-南通市图书馆

chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

中华医学杂志(英文版) 2024年第17期137卷 2017-2039页

作者： Li Jingnan Yao Hongwei Lu Yun Zhang Shutian Zhang Zhongtao Society of Digestive Endoscopy of the chinese medica. Association Colorectal Surgery Group of the chinese medica. Association chinese Association of Gastroenterologist & Hepatologist National clinical Research Center for Digestive Diseases chinese medica. journal clinical practie guideline collaborative Department of Gastroenterology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China Department of General Surgery Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Diseases Beijing China Department of General Surgery The Affiliated Hospital of Qingdao University Qingdao Shandong China Department of Gastroenterology Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Disease Beijing China

Background: The incidence and mortality of colorectal cancer (CRC) in China are increasing in recent years. The clarified pathogenesis and detectable precancerous lesions of CRC make it possible to prevent, screen, and diagnose CRC at an early stage. With the development of endoscopic and surgical techniques, the choice of treatment for early CRC is also worth further discussion, and accordingly, a standard follow-up program after treatment needs to be ***: This clinical practice guideline (CPG) was developed following the recommended process of the World Health Organization, adopting Grading of Recommendations Assessment, Development and Evaluation (GRADE) in assessing evidence quality, and using the Evidence to Decision framework to formulate clinical recommendations, thereby minimizing bias and increasing transparency of the CPG development process. We used the Reporting Items for practice guidelines in HealThcare (RIGHT) statement and Appraisal of guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline’s completeness and ***: This CPG comprises 46 recommendations concerning prevention, screening, diagnosis, treatment, and surveillance of CRC. In these recommendations, we have indicated protective and risk factors for CRC and made recommendations for chemoprevention. We proposed a suitable screening program for CRC based on the chinese context. We also provided normative statements for the diagnosis, treatment, and surveillance of CRC based on existing clinical evidence and ***: The 46 recommendations in this CPG are formed with consideration for stakeholders’ values and preferences, feasibility, and acceptability. Recommendations are generalizable to resource-limited settings with similar CRC epidemiology pattern as China.

关键词： Colorectal cancer Early detection of cancer Prevention Screening Diagnosis Treatment Follow-up guideline

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

引用

chinese medica. journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji Society of Digestive Endoscopy of the chinese medica. Association Colorectal Surgery Group of the chinese medica. Association chinese Association of Gastroenterologists&Hepatologists National clinical Research Center for Digestive Diseases chinese medica. journal clinical Practice guideline collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and Hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in China are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice guidelines in HealThcare(RIGHT)statement and the Appraisal of guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medica. *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers

引用

中华医学杂志(英文版) 2024年第19期

作者： Wang Xu’an Bai Yongrui Chai Ningli Li Yexiong Linghu Enqiang Wang Liwei Liu Yingbin Society of Hepato-pancreatobiliary Surgery of chinese Research Hospital Association Society of Digestive Endoscopy of the chinese medica. Association chinese medica. journal clinical Practice guideline collaborative Department of Biliary and Pancreatic Surgery Renji Hospital Shanghai Jiao Tong University School of Medicine State Key Laboratory of Systems Medicine for Cancers Shanghai Cancer Institute Shanghai Key Laboratory for Cancer Systems Regulation and clinical Translation Shanghai China Department of Radiation Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Gastroenterology and Hepatology the First Medical Center Chinese People’s Liberation Army General Hospital Beijing China State Key Laboratory of Molecular Oncology and Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Beijing China State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Department of Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China

Background: Biliary tract carcinoma (BTC) is relatively rare and comprises a spectrum of invasive tumors arising from the biliary tree. The prognosis is extremely poor. The incidence of BTC is relatively high in Asian countries, and a high number of cases are diagnosed annually in China owing to the large population. Therefore, it is necessary to clarify the epidemiology and high-risk factors for BTC in China. The signs associated with BTC are complex, often require collaborative treatment from surgeons, endoscopists, oncologists, and radiation therapists. Thus, it is necessary to develop a comprehensive chinese guideline for ***: This clinical practice guideline (CPG) was developed following the process recommended by the World Health Organization. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty of evidence and make recommendations. The full CPG report was reviewed by external guideline methodologists and clinicians with no direct involvement in the development of this CPG. Two guideline reporting checklists have been adhered to: Appraisal of guidelines for Research and Evaluation (AGREE) and Reporting Items for practice guidelines in Healthcare (RIGHT).Results: The guideline development group, which comprised 85 multidisciplinary clinical experts across China. After a controversies conference, 17 clinical questions concerning the prevention, diagnosis, and treatment of BTC were proposed. Additionally, detailed descriptions of the surgical principles, perioperative management, chemotherapy, immunotherapy, targeted therapy, radiotherapy, and endoscopic management were ***: The guideline development group created a comprehensive chinese guideline for the diagnosis and treatment of BTC, covering various aspects of epidemiology, diagnosis, and treatment. The 17 clinical questions have important reference value for the management of BTC.

关键词： Biliary tract carcinoma Etiology Diagnosis Treatment Surgery

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

舒巴坦治疗神经外科重症患者鲍曼不动杆菌感染中国专家共识

引用

中国现代神经疾病杂志 2024年第6期24卷 407-424页

作者：中华医学会神经外科学分会中国神经外科重症管理协作组石广志赵经纬左玮徐明胡付品不详首都医科大学附属北京天坛医院重症医学科 100070 中国医学科学院北京协和医学院北京协和医院药剂科复旦大学附属华山医院抗生素研究所

多重耐药或广泛耐药鲍曼不动杆菌感染的神经外科重症患者治疗难度大、病死率高。舒巴坦是治疗多重耐药鲍曼不动杆菌感染的有效药物,具有穿透炎性血脑屏障的优势,适用于神经外科重症患者。近年随着鲍曼不动杆菌对舒巴坦的耐药趋势日益严... 详细信息

多重耐药或广泛耐药鲍曼不动杆菌感染的神经外科重症患者治疗难度大、病死率高。舒巴坦是治疗多重耐药鲍曼不动杆菌感染的有效药物,具有穿透炎性血脑屏障的优势,适用于神经外科重症患者。近年随着鲍曼不动杆菌对舒巴坦的耐药趋势日益严峻,舒巴坦治疗多重耐药或广泛耐药鲍曼不动杆菌感染药物剂量、给药途径、联合方案等缺乏规范化标准。中国神经外科重症管理协作组通过梳理相关循证医学证据并经过反复讨论修改后形成《舒巴坦治疗神经外科重症患者鲍曼不动杆菌感染中国专家共识》,涵盖28条共识建议,为舒巴坦在神经外科重症管理中的应用提供科学、可行的临床指导。

关键词：神经外科手术危重病人医疗鲍氏不动杆菌舒巴克坦诊疗指南

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

chinese Stroke Association guidelines for clinical management of cerebrovascular disorders:executive summary and 2019 update on organizational stroke management

引用

Stroke & Vascular Neurology 2020年第3期5卷 260-269页

作者： Min Lou Jing Ding Bo Hu Yusheng Zhang Hao Li ZeFeng Tan Yan Wan An-Ding Xu chinese Stroke Association Stroke Council guideline Writing Committee Department of Neurology The Second Affilliated Hospital of Zhejiang UniversitySchool of MedicineHangzhouChina Department of Neurology Zhongshan Hospital Fudan UniversityShanghaiChina Department of Neurology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina Department of Neurology and Stroke Center The First Affiliated HospitalJinan UniversityGuangzhouChina Beijing Tiantan Hospital Capital Medical UniversityBeijingChina 不详

Aim Stroke is characterised by high morbidity,mortality and disability,which seriously affects the health and safety of the *** has become a serious public health problem in *** stroke management can significantly reduce the mortality and disability rates of patients with *** provide this evidence-based guideline to present current and comprehensive recommendations for organisational stroke *** A formal literature search of MEDLINE(1 January 1997 through 30 September 2019)was *** were synthesised with the use of evidence *** group members met by teleconference to discuss data-derived *** chinese Stroke Association’s Levels of Evidence grading algorithm was used to grade each *** Evidence-based guidelines are presented for the organisational management of patients presenting with *** focus of the guideline was subdivided into prehospital first aid system of stroke,rapid diagnosis and treatment of emergency in stroke centre,organisational management of stroke unit and stroke clinic,construction of regional collaborative network among stroke centres and evaluation and continuous improvement of stroke medica. *** The guidelines offer an organisational stroke management model for patients with stroke which might help dramatically.

关键词： diagnosis centre tables

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

慢性乙型肝炎中西医结合诊疗专家共识

引用

临床肝胆病杂志 2024年第5期40卷 884-892页

作者：中国医师协会中西医结合医师分会肝病学专家委员会王宪波徐小元郭朋中国医师协会中西医结合医师分会肝病学专家委员会

慢性乙型肝炎(CHB)仍是我国重大公共卫生问题,未经有效控制可进一步发展为肝硬化、肝癌,带来巨大社会经济负担。目前西医抗病毒治疗是其主要治疗方式,中西医结合治疗是我国CHB的特色治疗手段,两者优势互补可提高临床疗效。为推广中西医... 详细信息

慢性乙型肝炎(CHB)仍是我国重大公共卫生问题,未经有效控制可进一步发展为肝硬化、肝癌,带来巨大社会经济负担。目前西医抗病毒治疗是其主要治疗方式,中西医结合治疗是我国CHB的特色治疗手段,两者优势互补可提高临床疗效。为推广中西医结合协同诊疗理念,促进CHB中西医结合诊疗技术发展,建立规范化、标准化疾病诊断和治疗方案,中国医师协会中西医结合医师分会肝病学专家委员会牵头成立共识专家组,讨论并制定《慢性乙型肝炎中西医结合诊疗专家共识》,从CHB的流行病学、发病机制与病因病机、中西医结合诊断与辨证分型、中西医结合治疗四个方面阐述中西医结合协同诊疗理念并提供推荐意见,期望改善CHB患者预后,提高生活质量。

关键词：乙型肝炎,慢性中西医结合诊疗准则

来源：

维普期刊数据库博看期刊

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

guideline of Prevention and Treatment for Chronic Hepatitis B (2nd Version)

引用

journal of clinical and Translational Hepatology 2017年第4期5卷 297-318页

作者： Jinlin Hou Guiqiang Wang Fusheng Wang Jun Cheng Hong Ren Hui Zhuang Jian Sun Lanjuan Li Jie Li Qinghua Meng Jingmin Zhao Zhongping Duan Jidong Jia Hong Tang Jifang Sheng Jie Peng Fengmin Lu Qing Xie Lai Wei chinese Society of Hepatology,chinese medica. Association chinese Society of Infectious Diseases,chinese medica. Association Department of Infectious Diseases Nanfang HospitalSouthern Medical UniversityGuangzhouChina Department of Infectious Diseases Center for Liver DiseasesPeking University First HospitalBeijingChina The Institute of Translational Hepatology 302 Hospital of PLAPeking UniversityBeijingChina Center of Liver Diseases Beijing Ditan HospitalCapital Medical UniversityBeijingChina Institute for Viral Hepatitis the Key Laboratory of Molecular Biology for Infectious Diseasesthe second Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Microbiology of Peking University Health Science Center BeijingChina State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseasesthe First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouChina Serious Illness Medicine Inpatient Area Beijing Youan HospitalCapital Medical UniversityBeijingChina Department of Pathology 302 Hospital of PLAPeking UniversityBeijingChina Artificial Liver Center Beijing Youan HospitalCapital Medical UniversityBeijingChina Liver Research Center Beijing Friendship HospitalCapital Medical UniversityBeijingChina Center of Infectious Diseases West China Hospital of Sichuan UniversityDivision of Infectious DiseasesState Key Laboratory of BiotherapySichuan UniversityChengduChina Department of Infectious Diseases Shanghai Jiao Tong University School of Medicine Affiliated Ruijin HospitalShanghaiChina Hepatology Institute Peking University People's HospitalBeijingChina 不详

This guideline is established to standardize the prevention,diagnosis and antiviral therapy of chronic hepatitis B(CHB).For other treatment regimens and methods involving CHB,please refer to relevant guidelines and *** chinese Society of Hepatology,chinese medica. Association(CMA)and the Society of Infectious Diseases,CMA organized relevant native experts to establish this guideline of Prevention and Treatment for Chronic Hepatitis B(1st version)in 2005,and made the first revision in *** the past 5 years,great progress has been made in the native and foreign fundamental and clinical research with respect to CHB,necessitating additional revision of this guideline.

关键词： Hepatitis B Chronic Treatment Prevention guideline

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国多省市急性冠状动脉综合征住院患者治疗现状与指南差距分析

引用

中华心血管病杂志 2005年第9期33卷 789-792页

作者：中国急性冠状动脉综合征多中心临床研究协作组首都医科大学附属北京安贞医院心内科北京 100029

目的评价我国目前急性冠状动脉综合征(ACS)患者接受经循证医学证实有效的治疗措施应用现状。方法来自全国12家三级甲等医院注册,共1301例ACS患者住院期间接受不同的治疗措施,分析不同ACS患者接受再灌注现状及阿司匹林、血管紧张素转换... 详细信息

目的评价我国目前急性冠状动脉综合征(ACS)患者接受经循证医学证实有效的治疗措施应用现状。方法来自全国12家三级甲等医院注册,共1301例ACS患者住院期间接受不同的治疗措施,分析不同ACS患者接受再灌注现状及阿司匹林、血管紧张素转换酶抑制剂(ACEI)、β受体阻滞剂、低分子量肝素、他汀类调脂药物的临床应用情况。结果①急性ST段抬高心肌梗死(STEMI)患者不同时期药物使用情况:阿司匹林(95.9%～100.0%)、ACEI(72.0%～88.4%)、β受体阻滞剂(62.7%～74.5%)、低分子量肝素(84.7%～100.0%)、调脂药(72.5%～93.0%);②非ST段抬高心肌梗死(NSTEMI)及不稳定心绞痛(UA)患者阿司匹林(100.0%)、低分子量肝素在NSTEMI中的应用率(84.2%～100.0%)、UA中(65.1%～87.2%);③STEMI患者中有28.8%的患者未接受任何形式的再灌注治疗、12%的患者接受了单纯溶栓治疗、7.5%的患者接受了溶栓+经皮冠状动脉介入治疗(PCI)、48.9%的患者接受了PCI治疗;④50%的非ST段抬高的急性冠脉综合征(NSTEACS)患者接受了PCI治疗。结论在我国医疗水平较高的地区,经循证医学证实有效的治疗ACS措施在临床中的实际应用情况优于国外报告结果,但仍有较大的提升空间。

关键词：冠状动脉疾病治疗学规范急性冠状动脉综合征住院患者治疗现状血管紧张素转换酶抑制剂(ACEI) 非ST段抬高心肌梗死差距分析急性ST段抬高心肌梗死

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

中国肝静脉压力梯度临床应用专家共识(2018版)

引用

胃肠病学和肝病学杂志 2018年第12期27卷 1329-1340页

作者：无祁小龙张春清中国门静脉高压诊断与监测研究组(CHESS) 中华医学会消化病学分会微创介入协作组中国医师协会介入医师分会急诊介入专业委员会中华医学会消化病学分会肝胆疾病协作组中华医学会外科学分会脾脏及门静脉高压学组中华医学会肝病学分会脂肪肝和酒精性肝病学组中国研究型医院学会肝病专业委员会中华预防医学会肝胆胰疾病预防与控制专业委员会中华医学会数字医学分会中华医学会临床流行病学和循证医学分会南方医科大学南方医院肝病中心肝脏血流动力学实验室山东省立医院

门静脉高压是影响肝硬化患者临床预后的重要因素,其严重程度决定了肝硬化并发症(如食管胃静脉曲张破裂出血、腹腔积液、肝肾综合征等)的发生和发展[1-2]。据报道,我国肝病患者人数已超过4亿,是全球肝病负担最重的国家,其中乙型病毒性肝... 详细信息

门静脉高压是影响肝硬化患者临床预后的重要因素,其严重程度决定了肝硬化并发症(如食管胃静脉曲张破裂出血、腹腔积液、肝肾综合征等)的发生和发展[1-2]。据报道,我国肝病患者人数已超过4亿,是全球肝病负担最重的国家,其中乙型病毒性肝炎表面抗原阳性或丙型病毒性肝炎抗体阳性者约1.06亿,酒精性肝病患者约6000万,非酒精性脂肪性肝病患者约2亿[3-4]。尽管感染性肝病发病率较前有所下降,但非酒精性脂肪性肝病人数呈稳步上升趋势,预计到2030年将超过3.1亿[5]。

关键词：肝静脉压力梯度标准化门静脉高压诊疗规范

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

中医证候诊断标准研制指南

引用

中国循证医学杂志 2023年第9期23卷 993-998页

作者：世界中医药学会联合会呼吸疾病中医药防治省部共建协同创新中心河南中医药大学河南中医药大学第一附属医院李建生谢洋春柳王至婉不详河南中医药大学河南中医药大学第一附属医院

中医证候诊断标准的科学建立是实现中医诊治标准化、规范化的基础环节。目前证候诊断标准建立的思路与方法尚不明确,关键技术尚不完善,研制规范尚未形成,制约了证候诊断标准的建立及推广应用。因此,本研究结合前期已建立的中医证候标准... 详细信息

中医证候诊断标准的科学建立是实现中医诊治标准化、规范化的基础环节。目前证候诊断标准建立的思路与方法尚不明确,关键技术尚不完善,研制规范尚未形成,制约了证候诊断标准的建立及推广应用。因此,本研究结合前期已建立的中医证候标准研制技术体系及有关证候标准,起草了《中医证候诊断标准研制指南》,并征求相关专家意见进行了修改完善。本指南可供制订中医临床各科证候诊断标准时参考,同时适用于各级中医(中西医结合)医疗、教学机构及科研院所专业人员开展与中医证候诊断标准相关的临床、教学、科学研究。

关键词：证候诊断标准指南

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：